Literature DB >> 702462

Altitude sickness.

F M Hull.   

Abstract

Ten climbers were studied trekking from 1,950 to 4,650 m (6,500 ft to 15,500 ft) in the Nanda Devi Sanctuary of the Garwhal Himalaya. All developed altitude sickness, one seriously. Pulse, blood pressure, and peak flow rate were monitored daily in an attempt to predict the onset of altitude sickness. Prediction was uncertain though the one climber who became seriously cyanosed at 4,200 m (14,000 ft) had a consistently higher blood pressure than his colleagues.

Mesh:

Year:  1978        PMID: 702462      PMCID: PMC2158916     

Source DB:  PubMed          Journal:  J R Coll Gen Pract        ISSN: 0035-8797


  7 in total

1.  Physiological and medical aspects of the Himalayan scientific and mountaineering expedition, 1960-61.

Authors:  L G PUGH
Journal:  Br Med J       Date:  1962-09-08

2.  The heart at high altitude.

Authors:  F Jackson
Journal:  Br Heart J       Date:  1968-05

3.  Lung function test by peak-flow gauge at altitude.

Authors:  A Pines
Journal:  Lancet       Date:  1976-01-24       Impact factor: 79.321

4.  Letter: Lung-function test by airflometer at simulated altitude.

Authors:  D H Meyers
Journal:  Lancet       Date:  1976-01-10       Impact factor: 79.321

5.  Cerebral form of high-altitude illness.

Authors:  C S Houston; J Dickinson
Journal:  Lancet       Date:  1975-10-18       Impact factor: 79.321

6.  The incidence, importance, and prophylaxis of acute mountain sickness.

Authors:  P H Hackett; D Rennie; H D Levine
Journal:  Lancet       Date:  1976-11-27       Impact factor: 79.321

7.  Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension.

Authors:  A J Marshall; D W Barritt; J Pocock; S T Heaton
Journal:  Lancet       Date:  1977-02-05       Impact factor: 79.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.